In conclusion, although no effect was visible on macroscopic markers and CRP, this study shows that denosumab, RANKL inhibitor, reduced the proinflammatory cascades in the colonic mucosa and also had a beneficial effect on the composition of gut microbiota during progression of DNBS colitis. The gene discussed is CRP; the disease is colitis.